Research on the clinical value between gene polymorphism of HPA 1-6,9,15 and platelet transfusion refractoriness
10.3969/j.issn.1005-1678.2016.04.55
- VernacularTitle:患者HPA 1－6，9，15基因多态性对血小板输注无效的临床意义
- Author:
Yuan LI
;
Hui ZENG
;
Haibin WU
;
Xiaoyan ZHAO
;
Minchao YAN
;
Xiaojun GUO
- Publication Type:Journal Article
- Keywords:
human platelet allogntigens;
gene polymorphism;
platelet transfusion refractoriness;
percent platelet recorvery
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(4):173-175
- CountryChina
- Language:Chinese
-
Abstract:
Objective To research the clinical value between gene polymorphism of human platelet alloantigens (HPA) 1-6, 9, 15 and platelet transfusion refractoriness ( PTR) .Methods Totally 40 patients with platelet transfusion refractoriness( PTR) were randomly selected, and patients and donors’ peripheral blood specimens were collected and tested these samples with platelet GP specific antibodies, and judged the results of platelet transfusion, and with the help of the combination of PCR and direct sequencing for classification of HPA 1-6,9,15 antigens and observe the percent platelet recovery ( PPR ) after the same type of platelet transfusion, and explore the relationship between HPA gene polymorphism and PTR. Results There was no HPA-b gene was found neither on patients and donors’ HPA 1,4,9, showed the distribution of aa homozygous form; HPA 5,6 were mainly aa homozygous form, little bb homozygous form was discorvered.And HPA 2,3,15 were distributed of polymorphism, the frequency of HPA 2,3,5,6,15 were found with polymorphism.Conclusion For these patients who were happened with PRT many times, in addition to taking HLA into account, HPA gene polymorphism are also need to be considered.Most people only need to test patients and donors’ HPA2,3,15 gene to decrease the occurrence of PTR significantly when making HPA matching.
